How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Evidence generation plan

Closed for comments This consultation ended on at   Request commenting lead permission

6 Implementation considerations

The following considerations around implementing the evidence generation process have been identified through working with system partners:

Evidence generation period

  • To collect useful data on post-colonoscopy colorectal cancer rates, the length of data collection will need to be sufficient. Clinical advice suggests that 3 years of follow-up data is appropriate, so companies will need to be efficient in starting data collection.

  • Companies will need to be proactive about contacting national data registries, to ensure that data sharing agreements are in place.

Equalities

  • Data should be collected on ethnicity and analysed to assess any differences in diagnostic accuracy when the AI software is used for people from different ethnic backgrounds.

System considerations

  • When introducing AI-supported polyp detection, care should be taken to ensure that endoscopist skill and experience is not lost or fails to develop.

  • Companies should use dedicated and incentivised research staff, to reduce the burden on non-research staff.

  • Real-world data should be used when possible.

ISBN: [to be added at publication]